NCT00490152 is a clinical trial of Automated diary system in HIV Infections, sponsored by University of North Carolina, Chapel Hill.

Who is sponsoring NCT00490152?

NCT00490152 is sponsored by University of North Carolina, Chapel Hill.

What drugs are being tested in NCT00490152?

Interventions in NCT00490152: Automated diary system, Automated diary system, Automated diary system.

What condition does NCT00490152 study?

NCT00490152 studies HIV Infections.

Is NCT00490152 still recruiting?

NCT00490152 is currently completed. Last updated 27 February 2017.

Last reviewed 2017-02-27 · How we verify

NCT00490152

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microbicide-Use Adherence, Acceptability, and Attitudes Among Sexually Active Young Women Participating in a Phase I Microbicide Trial (MTN 004) "Tell Juliana"

Completed Last updated 27 February 2017

What this trial tests

trial testing Automated diary system in HIV Infections in 59 participants. Completed in 1 November 2009.

Timeline

1 August 2007

Primary endpoint
1 November 2009

1 November 2009

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Status	Completed
Study type	OBSERVATIONAL
Enrollment	59
Start date	1 August 2007
Primary completion	1 November 2009
Estimated completion	1 November 2009
Sites	3 locations across United States, Puerto Rico

Drugs / interventions tested

Automated diary system
Automated diary system
Automated diary system

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

University of North Carolina, Chapel Hill

Who can join

Adults 18 to 24, female only, with HIV Infections. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Microbicide use adherence as measured by a computerized phone diary
Time frame: 21 days(through end of study)
Microbicide use adherence as measured by e-mail messages
Time frame: 21 days (through end of study)
Microbicide use adherence as measured by in-depth interviews via teleconference
Time frame: 21 days (through end of study)
Microbicide use acceptability as measured by a computerized phone diary
Time frame: 21 days (through end of study)
Microbicide use acceptability as measured by e-mail messages
Time frame: 21 days (through end of study)
Microbicide use acceptability as measured by in-depth interviews via teleconferences
Time frame: 21 days (through end of study)

Sponsor's own description

ATN 062 is designed to gain scientific knowledge of microbicide-use adherence, acceptability, and attitudes among sexually active young women

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Dendrimers, an Emerging Opportunity in Personalized Medicine?
Caminade AM. · · 2022 · cited 39× · PMID 36013283 · DOI 10.3390/jpm12081334
Low dose versus high dose stavudine for treating people with HIV infection.
Magula N, Dedicoat M. · · 2015 · cited 6× · PMID 25627012 · DOI 10.1002/14651858.cd007497.pub2

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00490152 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
Last refreshed: 27 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00490152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing